Generics & Biosimilars | Association for Accessible Medicines
THANK YOU - for all those who made our first-ever #GRxBiosims virtual conference a success.
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
  • Celebrating 10 Years of Biosimilars
    Help reflect on these last 10 years and discuss how to make the next 10 years even better by trying our new Instagram lens and sharing your selfie with #b10similars in social media.
  • A group of five multi-ethnic seniors standing together in a park wearing casual clothing, smiling at the camera.
    Generic Savings Add Up for Patients with Cancer and Other Conditions
    No matter what condition you or your family members are experiencing, generic prescription drugs are saving you money.
  • AAM White Paper: Nitrosamines
    New White Paper: Nitrosamines
    The generics industry is eager to work with FDA to adopt a balanced risked-based approach to addressing the concerns around nitrosamines in medicines.
  • 2020 Generic Drug & Biosimilars  Access & Savings in the U.S. Report cover
    2020 Access & Savings in the U.S. Report
    The 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report details the economic benefit of generics and biosimilars to America’s patients. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing meds.
  • #SecureOurMeds
    Plan to Secure Our Medicines
    The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
    Watch Video
  • AAM Blueprint U.S. Supply Chain
    Securing the U.S. Rx Supply Chain
    The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.